Beaconlight Capital LLC Purchases 39,928 Shares of QuidelOrtho Corporation $QDEL

Beaconlight Capital LLC boosted its position in shares of QuidelOrtho Corporation (NASDAQ:QDEL) by 20.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 239,049 shares of the company’s stock after acquiring an additional 39,928 shares during the quarter. QuidelOrtho accounts for approximately 4.0% of Beaconlight Capital LLC’s investment portfolio, making the stock its 11th biggest holding. Beaconlight Capital LLC owned approximately 0.35% of QuidelOrtho worth $6,827,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Global Retirement Partners LLC raised its position in QuidelOrtho by 3,691.7% during the fourth quarter. Global Retirement Partners LLC now owns 910 shares of the company’s stock worth $26,000 after acquiring an additional 886 shares in the last quarter. Camelot Portfolios LLC acquired a new stake in QuidelOrtho during the 4th quarter valued at $29,000. Hantz Financial Services Inc. lifted its holdings in QuidelOrtho by 50.3% during the 4th quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company’s stock valued at $31,000 after purchasing an additional 362 shares during the last quarter. Larson Financial Group LLC lifted its holdings in QuidelOrtho by 322.2% during the 3rd quarter. Larson Financial Group LLC now owns 1,330 shares of the company’s stock valued at $39,000 after purchasing an additional 1,015 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd acquired a new stake in QuidelOrtho during the 3rd quarter valued at $63,000. 99.00% of the stock is owned by institutional investors.

QuidelOrtho Stock Down 7.0%

QDEL opened at $13.13 on Thursday. QuidelOrtho Corporation has a fifty-two week low of $9.92 and a fifty-two week high of $35.58. The company has a debt-to-equity ratio of 1.33, a quick ratio of 0.80 and a current ratio of 1.43. The company has a market capitalization of $895.33 million, a P/E ratio of -0.74 and a beta of 0.77. The stock has a fifty day moving average of $12.86 and a 200-day moving average of $20.96.

QuidelOrtho (NASDAQ:QDEL) last posted its earnings results on Tuesday, May 5th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.41). QuidelOrtho had a positive return on equity of 4.25% and a negative net margin of 45.57%.The firm had revenue of $619.80 million for the quarter, compared to analyst estimates of $665.23 million. During the same period in the prior year, the business posted $0.74 EPS. The firm’s quarterly revenue was down 10.5% compared to the same quarter last year. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. On average, equities analysts expect that QuidelOrtho Corporation will post 1.83 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on QDEL shares. UBS Group reaffirmed a “neutral” rating and set a $12.00 price target on shares of QuidelOrtho in a report on Thursday, May 7th. Citigroup cut their price target on QuidelOrtho from $30.00 to $13.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of QuidelOrtho in a report on Tuesday, April 21st. Wall Street Zen downgraded QuidelOrtho from a “buy” rating to a “hold” rating in a report on Sunday, April 12th. Finally, Zacks Research raised QuidelOrtho from a “strong sell” rating to a “hold” rating in a report on Monday. Four analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus price target of $14.88.

About QuidelOrtho

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.